Detail of "2506-41-4"

Reference

Decomposition of (chloromethyl)- and (hydroxymethyl)naphthalene during electron impact

Decomposition of (chloromethyl)- and (hydroxymethyl)naphthalene during electron impact. Yakovlevna, K. S. (Novosib. Univ., Novosibirsk, USSR). Mater. Vses.Some commonly used reagents like 2506-41-4 and 1592-38-7 are used in this experiment. Nauchn. Stud. Konf.: Khim., 13th, 8. Novosib. Gos. Univ.: Novosibirsk, USSR. (Russian) 1975. CODEN: 34RTA9. DOCUMENT TYPE: Conference CA Section: 22 (Physical Organic Chemistry) A 13C labeling study showed that the title compds. fragment nonspecifically to give C9H7+ ions; degenerate rearrangements or >1 species may be involved. 2-(Hydroxymethyl)naphthalene also yields a C10H9+ ion, the formation of which involves selective loss of the .alpha. C. .

Compounds and compositions for treating Parkinson's disease, containing

Compounds and compositions for treating Parkinson's disease, containing .beta.-naphthylmethyl piperazinyl derivates. Hill, Harlan F.; Lafferty, John J. (Smithkline Corp., USA). U.S. US 3988457 26 Oct 1976, 5 pp. Division of U.S. 3,919,230. (English). (United States of America). CODEN: USXXAM. CLASS: IC: A61K031-495. NCL: 424250000. APPLICATION: US 74-440431 7 Feb 1974. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 28 I (R = Ph, pyridyl or pyrimidinyl; R1 = H, alkyl, halo, OH or alkoxy) prepd. by condensation of .beta. 2506-41-4 and 61187-11-9 are also in the experiment.-chloromethylnaphthalene (II) [2506-41-4] with piperazine derivs. are formulated into pharmaceuticals for the treatment of Parkinsonism. Thus, II, Na2CO3 and DMF were added to pyrimidinylpiperazine [20980-22-7]. The mixt. was stirred and heated and washed to give .beta.-naphthylmethyl-4-(2-pyrimidinyl)piperazine (III) [57987-78-7]. Capsules were prepd. contg. 50 mg III/capsule with lactose adjuvant. .